CCCC Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03

Price $2.95

Market Cap (MRQ) $363M

P/E (TTM) -3.2

EPS (TTM) $-0.91

Revenue (TTM) $35M

ROE (TTM) -48.1%

52W Range $2–$5

CCCC Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04

range

bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

About C4 Therapeutics, Inc. - Common Stock Company overview from Wikipedia

05 · wikidata

Wikidata ↗

sectorHealthcare industryBiotechnology employees104 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06

Revenue$36M

2021-12-31 → 2025-12-31

EPS$-1.27

2021-12-31 → 2025-12-31

Free Cash Flow$-99M

2020-12-31 → 2025-12-31

Net margin-289.4%

2022-12-31 → 2025-12-31

Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric	CCCC	5Y avg	Peer Median	Verdict
P/E (TTM)	-3.25Y avg ≈-5.2	≈-5.2	·	·
P/S (TTM)	10.35Y avg ≈14.5	≈14.5	16.4	Fair value
P/B (MRQ)	1.55Y avg ≈1.7	≈1.7	2.6	Fair value
Price / FCF (TTM)	-4.25Y avg ≈-5.9	≈-5.9	·	·
Price / Cash Flow (TTM)	-4.35Y avg ≈-5.9	≈-5.9	·	·
Price / Tangible Book	1.15Y avg ≈1.7	≈1.7	·	·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric	CCCC	5Y avg	Peer Median	Verdict
Operating Margin (TTM)	-319.0%5Y avg ≈-435.8%	≈-435.8%	-164.6%	Weak
EBITDA Margin	-320.5%5Y avg ≈-435.8%	≈-435.8%	-164.6%	Weak
Pretax Margin	-291.7%5Y avg ≈-406.5%	≈-406.5%	-135.6%	Weak
Net Profit Margin (TTM)	-289.4%5Y avg ≈-409.6%	≈-409.6%	-245.9%	Below avg
ROA (TTM)	-30.9%5Y avg ≈-27.5%	≈-27.5%	-27.3%	In line
ROE (TTM)	-48.1%5Y avg ≈-43.1%	≈-43.1%	-21.3%	Below avg
ROIC	-45.0%5Y avg ≈-52.5%	≈-52.5%	-45.8%	In line

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric	5Y trend	CCCC	5Y avg	Peer Median	Verdict
Current Ratio (MRQ)		5.45Y avg ≈6.5	≈6.5	5.4	In line
Quick Ratio		2.35Y avg ≈2.7	≈2.7	2.7	Low liquidity

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric	5Y trend	CCCC	5Y avg	Peer Median	Verdict
Revenue YoY		1.0%5Y avg ≈1.8%	≈1.8%	·	·
Revenue CAGR 3Y		5.0%	·	·	·

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric	CCCC	5Y avg	Peer Median	Verdict
EPS (Diluted)	$-1.275Y avg ≈$-1.98	≈$-1.98	·	·
Revenue / Share	$0.435Y avg ≈$0.50	≈$0.50	·	·
Cash Flow / Share	$-1.195Y avg ≈$-1.61	≈$-1.61	·	·
Cash / Share	$0.775Y avg ≈$1.16	≈$1.16	·	·

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric	CCCC	5Y avg	Peer Median	Verdict
Asset Turnover	0.15Y avg ≈0.1	≈0.1	0.2	Weak
Receivables Turnover	13.15Y avg ≈7.4	≈7.4	7.9	Top tier
Revenue / Employee	≈$345.6K	·	·	·

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14

Avg Surprise 21.7%

Next Report Nov 04, 2026

Period	Report	EPS Actual	EPS Est	Surprise
June 30, 2026	Aug 5, 2026	$-0.18	$-0.23	22.0%
March 31, 2026		$-0.20	$-0.38	47.3%
Dec. 31, 2025		$-0.18	$-0.31	41.9%
Sept. 30, 2025		$-0.44	$-0.41	-6.2%
June 30, 2025		$-0.37	$-0.39	5.5%
March 31, 2025		$-0.37	$-0.46	19.4%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15

Income Statement 14

Metric	2025	2024	2023	2022	2021
Revenue	$36M	$36M	$21M	$31M	$46M
R&D Expense	$104M	$111M	$118M	$118M	$95M
SG&A Expense	$36M	$42M	$42M	$43M	$33M
Operating Expenses	$151M	$155M	$160M	$161M	$128M
Operating Income	$-115M	$-120M	$-139M	$-130M	$-82M
Other Non-op	$10M	$14M	$8M	$1M	$-2M
Pretax Income	$-105M	$-105M	$-131M	$-128M	$-84M
Income Tax	$121.0K	$131.0K	$1M	$0	$0
Net Income	$-105M	$-105M	$-132M	$-128M	$-84M
EPS (Basic)	$-1.27	$-1.52	$-2.67	$-2.62	$-1.82
EPS (Diluted)	$-1.27	$-1.52	$-2.67	$-2.62	$-1.82
Shares (Basic)	82,894,459	69,372,993	49,640,505	48,861,665	46,041,733
Shares (Diluted)	82,894,459	69,372,993	49,640,505	48,861,665	46,041,733
EBITDA	$-115M	$-120M	$-139M	$-130M	$-82M

Balance Sheet 22

Metric	2025	2024	2023	2022	2021
Cash & Equivalents	$75M	$55M	$127M	$30M	$76M
Short-term Investments	·	·	·	·	$233M
Receivables	$2M	$3M	$12M	$1M	$6M
Prepaid Expense	$7M	$10M	$6M	$10M	$11M
Current Assets	$258M	$258M	$271M	$288M	$326M
PP&E (Net)	$5M	$6M	$7M	$7M	$3M
PP&E (Gross)	$16M	$15M	$15M	$16M	$10M
Accum. Depreciation	$11M	$9M	$8M	$8M	$7M
Other Non-current Assets	$4M	$3M	$3M	$2M	$544.0K
Total Assets	$359M	$350M	$376M	$431M	$507M
Accounts Payable	$858.0K	$1M	$1M	$1M	$5M
Current Liabilities	$33M	$45M	$43M	$45M	$51M
Capital Leases	$54M	$60M	$66M	$71M	$31M
Total Liabilities	$102M	$134M	$130M	$142M	$117M
Long-term Debt	·	·	$0	$11M	$11M
Total Debt	·	·	$0	$11M	$11M
Common Stock	$9.0K	$7.0K	$6.0K	$5.0K	$5.0K
Retained Earnings	$-739M	$-634M	$-528M	$-396M	$-268M
AOCI	$50.0K	$53.0K	$-127.0K	$-4M	$-775.0K
Stockholders' Equity	$257M	$216M	$246M	$289M	$390M
Liabilities + Equity	$359M	$350M	$376M	$431M	$507M
Shares Outstanding	96,914,418	70,625,899	60,467,188	48,966,216	48,688,875

Cash Flow 13

Metric	2025	2024	2023	2022	2021
D&A	$2M	$2M	$2M	$2M	$1M
Stock-based Comp	$19M	$30M	$27M	$30M	$22M
Restructuring	$0	$2M	$0	·	·
Operating Cash Flow	$-99M	$-65M	$-107M	$-106M	$-87M
CapEx	$607.0K	$180.0K	$2M	$5M	$1M
Investing Cash Flow	$-9M	$-51M	$158M	$58M	$-189M
Stock Issued	·	·	$58M	$0	·
Stock Repurchased	$193.0K	$194.0K	$110.0K	$0	·
Net Stock Activity	$-193.0K	$-194.0K	$58M	·	·
Financing Cash Flow	$126M	$45M	$45M	$1M	$171M
Net Change in Cash	$19M	$-71M	$97M	$-46M	$-105M
Taxes Paid	$131.0K	$76.0K	·	·	·
Free Cash Flow	$-99M	$-65M	$-109M	$-111M	$-88M

Profitability 7

Metric	2025	2024	2023	2022	2021
Operating Margin	-320.5%	-336.1%	-669.8%	-416.6%	·
Net Margin	-292.1%	-296.0%	-638.3%	-412.2%	·
Pretax Margin	-291.7%	-295.6%	-632.2%	·	·
EBITDA Margin	-320.5%	-336.1%	-669.8%	-416.6%	·
ROA	-29.6%	-29.0%	-32.8%	-27.3%	-18.5%
ROE	-48.8%	-45.9%	-57.3%	-42.2%	-21.3%
ROIC	-45.0%	-55.5%	-57.0%	·	·

Liquidity & Solvency 4

Metric	2025	2024	2023	2022	2021
Current Ratio	7.8	5.7	6.3	6.5	6.4
Quick Ratio	2.3	1.3	3.2	0.7	6.1
Debt / Equity	·	·	0.0	0.0	0.0
LT Debt / Equity	·	·	0.0	0.0	0.0

Efficiency 2

Metric	Trend	2025	2024	2023	2022	2021
Asset Turnover		0.1	0.1	0.1	0.1	·
Receivables Turnover		13.1	4.8	3.1	8.7	·

Per Share 5

Metric	2025	2024	2023	2022	2021
Book Value / Share	$2.65	$3.06	$4.07	$5.91	$8.00
Revenue / Share	$0.43	$0.51	$0.42	$0.64	·
Cash Flow / Share	$-1.19	$-0.94	$-2.15	$-2.17	·
Cash / Share	$0.77	$0.79	$2.09	$0.61	$1.56
EPS (TTM)	$-1.27	$-1.52	$-2.67	$-2.62	$-1.82

Growth Rates 2

Metric	Trend	2025	2024	2023	2022	2021
Revenue YoY		1.0%	71.4%	-33.2%	-32.1%	·
Revenue CAGR 3Y		5.0%	-8.1%	·	·	·

Valuation (TTM) 14

Metric	2025	2024	2023	2022	2021
Revenue TTM	$36M	$36M	$21M	$31M	$46M
Net Income TTM	$-105M	$-105M	$-132M	$-128M	$-84M
Market Cap	$185M	$254M	$342M	$289M	$1.57B
Enterprise Value	·	·	$215M	$271M	$1.27B
P/E	-1.5	-2.4	-2.1	-2.3	-17.7
P/S	5.1	7.1	16.5	9.3	34.2
P/B	0.7	1.2	1.4	1.0	4.0
P / Tangible Book	0.7	1.2	1.4	1.0	4.0
P / Cash Flow	-1.9	-3.9	-3.2	-2.7	-18.0
P / FCF	-1.9	-3.9	-3.1	-2.6	-17.8
EV / EBITDA	·	·	-1.5	-2.1	-15.5
EV / FCF	·	·	-2.0	-2.4	-14.4
EV / Revenue	·	·	10.4	8.7	27.7
Earnings Yield	-66.5%	-42.2%	-47.3%	-44.4%	-5.7%

Income Statement 14

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue	$7M	$6M	$11M	$11M	$6M	$7M	$5M	$15M	$12M	$3M	$3M	$11M	$3M	$4M	$3M	$7M
R&D Expense	$24M	$25M	$25M	$26M	$26M	$27M	$33M	$32M	$24M	$23M	$30M	$28M	$30M	$29M	$31M	$30M
SG&A Expense	$9M	$9M	$9M	$9M	$9M	$9M	$10M	$12M	$10M	$10M	$10M	$11M	$10M	$11M	$10M	$10M
Operating Expenses	$33M	$34M	$34M	$46M	$35M	$36M	$43M	$44M	$33M	$35M	$41M	$39M	$40M	$40M	$41M	$39M
Operating Income	$-26M	$-28M	$-23M	$-34M	$-29M	$-29M	$-38M	$-28M	$-21M	$-32M	$-37M	$-28M	$-38M	$-36M	$-38M	$-32M
Other Non-op	$3M	$3M	$3M	$2M	$2M	$3M	$3M	$4M	$4M	$4M	$3M	$2M	$2M	$1M	$1M	$530.0K
Pretax Income	·	·	$-20M	$-32M	$-26M	$-26M	$-34M	$-25M	$-18M	$-28M	$-34M	$-26M	$-36M	$-35M	$-37M	$-32M
Income Tax	$0	$0	$121.0K	$0	$0	$0	$131.0K	$0	$0	$0	$277.0K	$1M	$0	$0	$0	$0
Net Income	$-24M	$-25M	$-20M	$-32M	$-26M	$-26M	$-35M	$-25M	$-18M	$-28M	$-35M	$-27M	$-36M	$-35M	$-37M	$-32M
EPS (Basic)	$-0.18	$-0.20	$-0.09	$-0.44	$-0.37	$-0.37	$-0.50	$-0.35	$-0.26	$-0.41	$-0.68	$-0.55	$-0.73	$-0.71	$-0.76	$-0.65
EPS (Diluted)	$-0.18	$-0.20	$-0.09	$-0.44	$-0.37	$-0.37	$-0.50	$-0.35	$-0.26	$-0.41	$-0.68	$-0.55	$-0.73	$-0.71	$-0.76	$-0.65
Shares (Basic)	130,696,742	126,074,555	·	72,563,311	71,005,743	70,833,044	·	69,627,190	68,810,259	68,432,168	·	49,212,126	49,063,631	49,032,319	·	48,921,928
Shares (Diluted)	130,696,742	126,074,555	·	72,563,311	71,005,743	70,833,044	·	69,627,190	68,810,259	68,432,168	·	49,212,126	49,063,631	49,032,319	·	48,921,928
EBITDA	$-26M	$-27M	·	$-34M	$-29M	$-29M	·	$-28M	$-21M	$-32M	·	$-28M	$-38M	$-36M	·	$-32M

Balance Sheet 22

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Cash & Equivalents	$79M	$61M	$75M	$59M	$78M	$51M	$55M	$60M	$73M	$90M	$127M	$61M	$45M	$49M	$30M	$50M
Short-term Investments	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	$264M
Receivables	$1M	$3M	$2M	$7M	$2M	$8M	$3M	$10M	$1M	$14M	$12M	$500.0K	$1M	$528.0K	$1M	$1M
Prepaid Expense	$8M	$7M	$7M	$8M	$8M	$9M	$10M	$7M	$11M	$8M	$6M	$7M	$6M	$8M	$10M	$10M
Current Assets	$263M	$245M	$258M	$207M	$225M	$233M	$258M	$273M	$276M	$280M	$271M	$224M	$274M	$278M	$288M	$325M
PP&E (Net)	$4M	$4M	$5M	$5M	$6M	$5M	$6M	$6M	$7M	$7M	$7M	$7M	$8M	$8M	$7M	$7M
PP&E (Gross)	$16M	$16M	$16M	$16M	$16M	$15M	$15M	$15M	$15M	$15M	$15M	$15M	$15M	$16M	$16M	$15M
Accum. Depreciation	$11M	$11M	$11M	$10M	$10M	$10M	$9M	$9M	$9M	$8M	$8M	$8M	$8M	$9M	$8M	$8M
Other Non-current Assets	$4M	$4M	$4M	$211.0K	$178.0K	$3M	$3M	$5M	$3M	$5M	$3M	$3M	$3M	$3M	$2M	$1M
Total Assets	$359M	$329M	$359M	$265M	$297M	$320M	$350M	$376M	$381M	$398M	$376M	$333M	$375M	$396M	$431M	$461M
Accounts Payable	$1M	$773.0K	$858.0K	$1M	$2M	$683.0K	$1M	$2M	$913.0K	$2M	$1M	$1M	$2M	$1M	$1M	$2M
Current Liabilities	$48M	$27M	$33M	$36M	$44M	$41M	$45M	$43M	$54M	$55M	$43M	$30M	$48M	$39M	$45M	$45M
Capital Leases	$50M	$52M	$54M	$55M	$57M	$58M	$60M	$61M	$63M	$64M	$66M	$67M	$68M	$70M	$71M	$72M
Total Liabilities	$112M	$95M	$102M	$111M	$122M	$124M	$134M	$133M	$134M	$140M	$130M	$117M	$141M	$134M	$142M	$143M
Long-term Debt	·	·	·	·	·	·	·	·	·	·	·	$0	$10M	$12M	$11M	$11M
Total Debt	·	·	·	·	·	·	·	·	·	·	·	·	·	$11M	·	$11M
Common Stock	$12.0K	$10.0K	$9.0K	$7.0K	$7.0K	$7.0K	$7.0K	$7.0K	$7.0K	$7.0K	$6.0K	$5.0K	$5.0K	$5.0K	$5.0K	$5.0K
Retained Earnings	$-787M	$-764M	$-739M	$-718M	$-686M	$-660M	$-634M	$-599M	$-574M	$-557M	$-528M	$-494M	$-467M	$-431M	$-396M	$-359M
AOCI	$-444.0K	$-322.0K	$50.0K	$87.0K	$-30.0K	$43.0K	$53.0K	$455.0K	$-440.0K	$-380.0K	$-127.0K	$-904.0K	$-2M	$-2M	$-4M	$-5M
Stockholders' Equity	$247M	$234M	$257M	$154M	$174M	$195M	$216M	$243M	$247M	$258M	$246M	$216M	$234M	$262M	$289M	$318M
Liabilities + Equity	$359M	$329M	$359M	$265M	$297M	$320M	$350M	$376M	$381M	$398M	$376M	$333M	$375M	$396M	$431M	$461M
Shares Outstanding	122,905,756	104,036,350	96,914,418	74,174,515	71,007,083	70,989,661	70,625,899	70,562,901	68,815,642	68,778,591	60,467,188	49,259,870	49,065,098	49,052,509	48,966,216	48,951,283

Cash Flow 11

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
D&A	$292.0K	$404.0K	·	$460.0K	$615.0K	$456.0K	·	$442.0K	$448.0K	$448.0K	·	$447.0K	·	·	·	·
Stock-based Comp	$3M	$3M	$4M	$5M	$5M	$6M	$8M	$9M	$6M	$6M	$6M	$8M	$6M	$6M	$7M	$6M
Other Non-cash	·	$-8M	·	·	·	$-13M	·	·	·	·	·	·	·	·	·	·
Operating Cash Flow	$-2M	$-30M	$-22M	$-31M	$-12M	$-33M	$-18M	$-24M	$-5M	$-18M	$-24M	$-31M	$-19M	$-33M	$-29M	$-28M
CapEx	$37.0K	$64.0K	$11.0K	$411.0K	$185.0K	$0	$-4.0K	$-13.0K	$197.0K	$0	$157.0K	$600.0K	$362.0K	$589.0K	$1M	$3M
Investing Cash Flow	$-15M	$16M	$-81M	$4M	$39M	$29M	$14M	$162.0K	$-12M	$-53M	$32M	$58M	$15M	$54M	$9M	$20M
Stock Repurchased	$0	$200.0K	$14.0K	$24.0K	$0	$155.0K	$0	$85.0K	$0	$109.0K	$0	$16.0K	$0	$94.0K	$0	$0
Net Stock Activity	·	$-200.0K	·	·	·	$-155.0K	·	·	·	$-109.0K	·	·	·	$-94.0K	·	·
Financing Cash Flow	$34M	$462.0K	$119M	$8M	$0	$-46.0K	$112.0K	$11M	$135.0K	$35M	$58M	$-11M	$-746.0K	$-684.0K	$47.0K	$361.0K
Net Change in Cash	$17M	$-13M	$16M	$-19M	$27M	$-4M	$-4M	$-13M	$-17M	$-37M	$66M	$16M	$-5M	$20M	$-20M	$-8M
Free Cash Flow	·	$-30M	·	·	·	·	·	·	·	$-18M	·	·	·	$-34M	·	·

Profitability 7

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Operating Margin	-397.9%	-451.6%	·	-306.4%	-441.0%	-402.9%	·	-183.9%	-178.6%	-1060.2%	·	-251.2%	-1410.2%	-963.8%	·	-481.0%
Net Margin	-355.9%	-408.5%	·	-286.4%	-402.6%	-363.7%	·	-160.6%	-147.6%	-933.2%	·	-244.2%	-1348.4%	-925.2%	·	-473.2%
Pretax Margin	·	·	·	-286.4%	-402.6%	-363.7%	·	-160.6%	-147.6%	-933.2%	·	-235.1%	·	·	·	·
EBITDA Margin	-397.9%	-445.1%	·	-306.4%	-441.0%	-396.6%	·	-183.9%	-178.6%	-1060.2%	·	-251.2%	-1410.2%	-963.8%	·	-481.0%
ROA	-7.2%	-7.8%	·	-8.8%	-6.6%	-7.6%	·	·	·	-7.8%	·	·	·	-7.6%	·	-6.6%
ROE	-11.2%	-11.7%	·	-13.6%	-10.0%	-12.0%	·	·	·	-12.0%	·	·	·	-11.1%	·	-8.9%
ROIC	·	·	·	-22.3%	·	-14.9%	·	·	·	-12.5%	·	·	·	·	·	·

Liquidity & Solvency 4

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Current Ratio	5.4	9.0	·	5.8	5.1	5.7	·	·	·	5.1	·	·	·	7.1	·	7.2
Quick Ratio	1.7	2.4	·	1.8	1.8	1.5	·	·	·	1.9	·	·	·	1.3	·	7.0
Debt / Equity	·	·	·	·	·	·	·	·	·	·	·	·	·	0.0	·	0.0
LT Debt / Equity	·	·	·	·	·	·	·	·	·	·	·	·	·	0.0	·	0.0

Efficiency 2

Metric	Trend	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Asset Turnover		0.0	0.0	·	0.0	0.0	0.0	·	·	·	0.0	·	·	·	0.0	·	0.0
Receivables Turnover		3.8	1.1	·	2.8	3.3	0.8	·	·	·	0.4	·	·	·	3.3	·	2.1

Per Share 5

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Book Value / Share	$2.01	$2.25	·	$2.08	$2.45	$2.75	·	·	·	$3.76	·	·	·	$5.35	·	$6.50
Revenue / Share	$0.05	$0.05	·	$0.15	$0.09	$0.10	·	$0.22	$0.17	$0.04	·	$0.23	$0.05	$0.08	·	$0.14
Cash Flow / Share	·	$-0.24	·	·	·	$-0.47	·	·	·	$-0.26	·	·	·	$-0.68	·	·
Cash / Share	$0.64	$0.59	·	$0.79	$1.10	$0.72	·	·	·	$1.30	·	·	·	$1.01	·	$1.01
EPS (TTM)	$-0.91	$-1.10	·	$-1.68	$-1.59	$-1.48	·	$-1.70	$-1.90	$-2.37	·	$-2.75	$-2.85	$-2.68	·	$-2.17

Valuation (TTM) 11

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue TTM	$35M	$35M	·	$30M	$34M	$40M	·	$34M	$29M	$20M	·	$20M	$16M	$27M	·	$48M
Net Income TTM	$-101M	$-104M	·	$-119M	$-112M	$-103M	·	$-105M	$-108M	$-126M	·	$-135M	$-140M	$-131M	·	$-107M
Market Cap	$574M	$274M	·	$165M	$102M	$114M	·	·	·	$562M	·	·	·	$154M	·	$429M
Enterprise Value	·	·	·	·	·	·	·	·	·	·	·	·	·	$115M	·	$127M
P/E	-5.1	-2.4	·	-1.3	-0.9	-1.1	·	-3.4	-2.4	-3.4	·	-0.7	-1.0	-1.2	·	-4.0
P/S	16.4	7.8	·	5.5	3.0	2.9	·	·	10.8	28.0	·	4.5	8.4	5.7	·	8.9
P/B	2.3	1.2	·	1.1	0.6	0.6	·	·	·	2.2	·	·	·	0.6	·	1.3
P / Tangible Book	2.3	1.2	·	1.1	0.6	0.6	·	·	·	2.2	·	·	·	0.6	·	1.3
P / Cash Flow	·	-9.1	·	·	·	-3.4	·	·	·	-31.0	·	·	·	-4.6	·	·
EV / Revenue	·	·	·	·	·	·	·	·	·	·	·	1.5	6.3	4.2	·	2.6
Earnings Yield	-19.5%	-41.8%	·	-75.7%	-111.2%	-92.5%	·	-29.8%	-41.1%	-29.0%	·	-147.8%	-103.6%	-85.4%	·	-24.7%

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	$36M	$36M	$21M	$31M	$46M
Operating Margin %	-320.5%	-336.1%	-669.8%	-416.6%	·
Net Income	$-105M	$-105M	$-132M	$-128M	$-84M
Diluted EPS	$-1.27	$-1.52	$-2.67	$-2.62	$-1.82

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Debt / Equity	·	·	0.0	0.0	0.0
Current Ratio	7.8	5.7	6.3	6.5	6.4
Quick Ratio	2.3	1.3	3.2	0.7	6.1

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow	$-99M	$-65M	$-109M	$-111M	$-88M

Institutional owners (13F) 162 filers · $544.7M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 162

Value held $544.7M

New positions 55

Exited positions 25

Institutional activity — Q2 2026 vs prior quarter

New positions	Exited positions	Increased	Decreased	Net shares change
55 (+18 vs prior Q)	25 (+16 vs prior Q)	54 (+11 vs prior Q)	30 (+1 vs prior Q)	+30.8M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution	Value	Shares	% of tracked 13F	Type
MORGAN STANLEY	$41,410,468	8,867,338	7.60%	Shares
RA CAPITAL MANAGEMENT, L.P.	$37,360,000	8,000,000	6.86%	Shares
BlackRock, Inc.	$36,877,672	7,896,718	6.77%	Shares
Lynx1 Capital Management LP	$34,215,647	7,326,691	6.28%	Shares
Squadron Capital Management LLC	$33,624,000	7,200,000	6.17%	Shares
Bain Capital Life Sciences Investors, LLC	$33,492,820	7,171,910	6.15%	Shares
JPMORGAN CHASE & CO	$20,651,295	4,747,424	3.79%	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$20,630,804	4,417,731	3.79%	Shares
CITADEL ADVISORS LLC	$19,555,999	4,187,580	3.59%	Shares
GOLDMAN SACHS GROUP INC	$16,489,728	3,530,991	3.03%	Shares
TWO SIGMA INVESTMENTS, LP	$16,203,532	3,469,707	2.97%	Shares
Soleus Capital Management, L.P.	$15,775,171	3,377,981	2.90%	Shares
SILVERARC CAPITAL MANAGEMENT, LLC	$14,159,720	3,032,060	2.60%	Shares
BANK OF AMERICA CORP /DE/	$12,405,197	2,656,359	2.28%	Shares
GEODE CAPITAL MANAGEMENT, LLC	$11,780,697	2,522,163	2.16%	Shares
Ikarian Capital, LLC	$11,362,110	2,433,000	2.09%	Shares
STATE STREET CORP	$9,879,950	2,115,621	1.81%	Shares
Candriam S.C.A.	$8,383,622	1,796,937	1.54%	Shares
VANGUARD GROUP INC	$8,365,446	4,379,815	1.54%	Shares
D. E. Shaw & Co., Inc.	$8,130,419	1,740,989	1.49%	Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$8,089,421	1,732,210	1.49%	Shares
WASATCH ADVISORS LP	$7,789,431	2,961,761	1.43%	Shares
Patient Square Capital LP	$7,513,166	1,608,815	1.38%	Shares
HighVista Strategies LLC	$6,295,800	1,348,136	1.16%	Shares
RENAISSANCE TECHNOLOGIES LLC	$5,556,497	1,189,828	1.02%	Shares
DIMENSIONAL FUND ADVISORS LP	$5,546,166	1,188,507	1.02%	Shares
NORTHERN TRUST CORP	$5,419,754	1,160,547	0.99%	Shares
CONGRESS ASSET MANAGEMENT CO	$4,686,051	1,003,437	0.86%	Shares
FMR LLC	$4,175,231	894,054	0.77%	Shares
UBS Group AG	$3,871,289	828,970	0.71%	Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$3,647,550	781,060	0.67%	Shares
BOOTHBAY FUND MANAGEMENT, LLC	$3,438,666	736,331	0.63%	Shares
VANGUARD PORTFOLIO MANAGEMENT LLC	$3,176,039	680,094	0.58%	Shares
VANGUARD FIDUCIARY TRUST CO	$2,844,712	609,146	0.52%	Shares
ExodusPoint Capital Management, LP	$2,709,511	580,195	0.50%	Shares
Velan Capital Investment Management LP	$2,661,900	570,000	0.49%	Shares
STEMPOINT CAPITAL LP	$2,445,436	523,648	0.45%	Shares
Rockefeller Capital Management L.P.	$2,315,465	495,817	0.43%	Shares
Nuveen, LLC	$2,260,326	484,010	0.41%	Shares
WELLS FARGO & COMPANY/MN	$2,114,113	452,701	0.39%	Shares
TWO SIGMA ADVISERS, LP	$2,040,262	1,068,200	0.37%	Shares
Man Group plc	$1,908,386	408,648	0.35%	Shares
Squadron Capital Management LLC	$1,868,000	400,000	0.34%	Call option
PLATINUM INVESTMENT MANAGEMENT LTD	$1,796,857	384,766	0.33%	Shares
Seven Fleet Capital Management LP	$1,780,059	381,169	0.33%	Shares
Qube Research & Technologies Ltd	$1,730,487	370,554	0.32%	Shares
Atom Investors LP	$1,701,519	364,351	0.31%	Shares
Susquehanna Portfolio Strategies, LLC	$1,564,819	335,079	0.29%	Shares
ADAGE CAPITAL PARTNERS GP, L.L.C.	$1,517,750	325,000	0.28%	Shares
JANE STREET GROUP, LLC	$1,413,843	302,750	0.26%	Shares

Show all 162 institutional owners →

Activists & 5%+ owners 1 position

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer	Filed	Stake	Status	Purpose	Filing
Cobro Ventures Opportunity Fund, L.P., Cobro Opportunity Fund GP, LLC, Marc Cohen, Alain Cohen, Todd Kaloudis ×2 filings	June 15, 2021	·	Initial filing	·	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 27 insiders · 13 officers · 15 directors

19

Insider	Role	Last activity	Shares owned	Sells 12m	Net 12m
Andrew Hirsch	President & CEO	Feb. 15, 2026 F	1,074,934	0	$0
Kendra Adams	Chief Financial Officer	Sept. 18, 2026 F	382,323	0	$0
Lauren White	Chief Financial Officer	Aug. 30, 2023 M	32,686	0	$0
William Mckee	Chief Financial Officer	Oct. 6, 2020 P	5,263	0	$0
Leonard Reyno	Chief Medical Officer	July 10, 2026 F	372,406	1	$-22,200
Paige Mahaney	Chief Scientific Officer	Feb. 14, 2026 F	336,910	0	$0
Mark Mossler	Chief Accounting Officer	Feb. 14, 2026 F	71,916	0	$0
Scott N Boyle	Chief Business Officer	Feb. 14, 2026 F	298,801	0	$0
Kelly Schick	Chief People Officer	Feb. 14, 2026 F	299,881	0	$0
Jolie Siegel	Chief Legal Officer	Feb. 14, 2025 A	107,939	0	$0
Stewart Fisher	Chief Scientific Officer	Sept. 16, 2024 M	130,710	0	$0
Adam Crystal	Chief Medical Officer	Jan. 30, 2023 M	20,097	0	$0
Laura Jean Wahlberg	VP of Finance Corp Controller	Feb. 11, 2021 A	·	0	$0
Kenneth Carl Anderson	Director	Oct. 1, 2026 A	75,612	0	$0
Donna Roy Grogan	Director	Oct. 1, 2026 A	79,471	0	$0
Stephen Fawell	Director	June 24, 2026 A	·	0	$0
Laura Bessen	Director	June 24, 2026 A	·	0	$0
Utpal Koppikar	Director	June 24, 2026 A	5,667	0	$0
Ronald Harold Wilfred Cooper	Director	June 24, 2026 A	·	0	$0
Owen Hughes	Director	June 24, 2026 A	·	0	$0
Steven L. Hoerter	Director	June 24, 2026 A	·	0	$0
Malcolm Salter	Director	June 20, 2024 A	11,380	0	$0
Bruce Downey	Director	June 20, 2024 A	489,542	0	$0
Glenn Dubin	Director	April 1, 2024 A	22,075	0	$0
Marc A Cohen	Director	June 22, 2022 A	1,118	0	$0
Alain J Cohen	Director	April 4, 2022 A	928	0	$0
Elena Prokupets	Director	Sept. 27, 2021 S	503,126	0	$0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 20 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund	Weight	Units	As of	Source
QQQS · Invesco Exchange-Traded Fund Trust …	0.44%	32,308 SH	Oct. 2, 2026	Daily
IWC · iShares Trust	0.08%	342,369 SH	Sept. 11, 2026	Daily
VTWV · VANGUARD SCOTTSDALE FUNDS	0.03%	88,122 SH	Aug. 19, 2026	Daily
IBB · iShares Trust	0.03%	845,464 SH	Sept. 11, 2026	Daily
PRFZ · Invesco Exchange-Traded Fund Trust	0.03%	232,512 SH	Oct. 2, 2026	Daily
IBBQ · Invesco Exchange-Traded Fund Trust …	0.03%	8,690 SH	Oct. 2, 2026	Daily
IWM · iShares Trust	0.01%	2,614,567 SH	Sept. 11, 2026	Daily
RSSL · Global X Funds	0.01%	48,213 NS	July 31, 2026	N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS	0.01%	583,446 SH	Aug. 19, 2026	Daily
DFAS · Dimensional ETF Trust	0.01%	235,215 NS	July 31, 2026	N-PORT
DXUV · Dimensional ETF Trust	0.00%	3,906 NS	July 31, 2026	N-PORT
DCOR · Dimensional ETF Trust	0.00%	14,611 NS	July 31, 2026	N-PORT
DFSU · Dimensional ETF Trust	0.00%	8,504 NS	July 31, 2026	N-PORT
DFAC · Dimensional ETF Trust	0.00%	115,180 NS	July 31, 2026	N-PORT
DFAU · Dimensional ETF Trust	0.00%	19,202 NS	July 31, 2026	N-PORT
DFUS · Dimensional ETF Trust	0.00%	21,036 NS	July 31, 2026	N-PORT
VXF · VANGUARD INDEX FUNDS	0.00%	1,046,993 SH	Aug. 19, 2026	Daily
VTI · VANGUARD INDEX FUNDS	0.00%	3,264,924 SH	Aug. 19, 2026	Daily
VTHR · VANGUARD SCOTTSDALE FUNDS	0.00%	8,526 SH	Aug. 19, 2026	Daily
IWN · iShares Trust	·	926,223 SH	Sept. 11, 2026	Daily

CCCC Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21

rating · 13 analysts BUY

Median target $11.00 +272.9%

4 30.8% Strong Buy

8 61.5% Buy

1 7.7% Hold

0 0.0% Sell

0 0.0% Strong Sell

12-Month Price Target

6 analysts · 2026-09-30

Mean target $13.33 +352.0%

← Below all targets Current price $2.95

Low$7.00 Mean$13.33 High$30.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker	Market Cap	P/E	Rev YoY	Net Margin	ROE	Gross Margin
CCCC	$185M	-1.5	1.0%	-292.1%	-48.8%	·
MYGN	$575M	-1.6	-1.6%	-44.4%	-96.8%	69.9%
RZLT	$501M	-6.9	·	·	-67.8%	·
KYTX	$568M	-2.6	·	·	-77.4%	·
SPRY	$1.16B	-6.7	-5.5%	-203.3%	-111.8%	·
EIKN	·	·	·	·	·	·
EDIT	$201M	-1.1	25.4%	-395.0%	-688.8%	·
GALT	$271M	-8.7	·	·	25.0%	·
IRD	$140M	-2.5	29.1%	-349.3%	-302.2%	·
AGEN	$111M	·	10.4%	-2.7%	1.0%	·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

CCCC C4 Therapeutics, Inc. - Common Stock